Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2020

Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

GlobeNewswire October 22, 2020

Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

GlobeNewswire October 12, 2020

Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC)

PR Newswire October 9, 2020

Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

GlobeNewswire September 23, 2020

Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

GlobeNewswire September 10, 2020

Athenex, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire September 8, 2020

Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers

GlobeNewswire September 8, 2020

Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

GlobeNewswire September 1, 2020

Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners

GlobeNewswire August 6, 2020

Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2020

Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors

GlobeNewswire August 4, 2020

Athenex, Inc. to Report Second Quarter 2020 Earnings Results on August 6, 2020

GlobeNewswire July 27, 2020

Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel

GlobeNewswire June 23, 2020

Athenex Announces $225 Million Loan Agreement with Oaktree

GlobeNewswire June 22, 2020

Athenex Oncology launches Facing MBC Together campaign to address isolation for people living with metastatic breast cancer

PR Newswire June 13, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX

GlobeNewswire June 8, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX

GlobeNewswire June 3, 2020

Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program

GlobeNewswire May 29, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX

ACCESSWIRE IA May 25, 2020